Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .

Essential

These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.
Statistics

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Cancer Treatment with Heavy Ions: Knowhow from the German Cancer Research Center Ensures Precision and Safety

No. 48 | 26/10/2009 | by (Koh)

On November 2, 2009, the Heidelberg Ion Therapy Center (HIT) will be opened. Very soon the first patients with malignant tumors will be treated in the new high-tech facility. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have contributed substantially to the launch of this worldwide unique treatment facility, which is operated by Heidelberg University Hospitals.

Illustration of the treatment planning with heavy ions
© dkfz.de

To launch an ambitious technology project like HIT, a collaboration of scientists from a multitude of disciplines is needed. Ever since first plans to use the particle accelerator of the GSI Center for Heavy Ion Research in Darmstadt for cancer radiation therapy arose in the early 1990s, scientists at the German Cancer Research Center (DKFZ) have been involved in the technical, physical and medical developments that followed. At DKFZ, medical physicists from the department of Professor Wolfgang Schlegel, in particular, have made essential contributions to the fact that this effective type of treatment is now available for the benefit of many patients at the Heidelberg facility.

A heavy ion therapy is planned for each patient individually on the basis of CT scans. Specially developed software transfers information from the image data in such a way that in every point of the tumor the required radiation dose is administered. The tools for therapy planning were developed by physicists and computer scientists of DKFZ jointly with colleagues at GSI for the pilot phase of heavy ion therapy in Darmstadt. The programs now used by Siemens for operating HIT are based on this collaborative software development.

When patients are to be treated in a gigantic facility like HIT, safety comes first. Risk management has been the responsibility of DKFZ researchers who are now working at HIT. They have created binding guidelines for every process step. Quality assurance of therapy is based primarily on the developments by DKFZ for the pilot project in Darmstadt and has now been transferred to the Heidelberg facility. Thus, prior to each actual radiation treatment, a ‘phantom’ model of the patient is irradiated. The therapy plan is only approved if these measurements show that precisely the calculated radiation dose reaches the tumor and there is no damage to healthy tissue.

High precision dose of the radiation beam, as it is achieved by the raster scan method in heavy ion therapy, is beneficial for the patient only if the tumor is exactly in the position determined by the physicians. This is achieved by stereotactic positioning systems which were developed at DKFZ and have been optimized jointly with colleagues at HIT for heavy ion radiation therapy.

DKFZ scientists also contributed substantially to the study of the biological effect of ion radiation on tumor tissue and on normal tissue. These experiments, which were initially performed at GSI, are continued at HIT in order to further improve predictions of the radiation effect in patients.

The Deutsche Forschungsgemeinschaft (DFG) and the Helmholtz Association are both providing financial support for the collaboration of DKFZ scientists and scientists at HIT, radiotherapists of Heidelberg University Hospitals and scientists at GSI.

A picture illustrating the treatment planning with heavy ions is available at:

http://www.dkfz.de/de/presse/pressemitteilungen/2009/images/Bestrahlungsplanung_Schwerionen.jpg

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.

RSS-Feed

Subscribe to our RSS-Feed.

to top
powered by webEdition CMS